Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow EKSO BIONICS HOLDINGS, INC.

Get SEC filing alerts via email and in your feed for EKSO BIONICS HOLDINGS, INC.

EKSO

EKSO BIONICS HOLDINGS, INC.

About EKSO BIONICS HOLDINGS, INC.

Ekso Bionics Holdings, Inc. designs and markets exoskeleton devices that enhance human mobility, strength, and endurance. Its core products include wearable robotic exoskeletons for medical rehabilitation and personal mobility, serving healthcare providers, veterans, and individuals with disabilities. The company operates globally, focusing on regulatory compliance, clinical validation, and competitive innovation in the medical and industrial robotics sectors.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from EKSO BIONICS HOLDINGS, INC.

1
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports 37% Revenue Decline and Increased Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports 29% Revenue Decline and $11.7 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports Q3 2025 Revenue Increase Amid Operational Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports 58% Revenue Decline in Q2 2025, Net Loss Increases

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports $3.375 Million Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports $17.9 Million Revenue for Fiscal Year 2024, Faces Operational Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
EKSO BIONICS HOLDINGS, INC. Ekso Bionics Reports 10% Revenue Decline, Improved Net Loss and Operating Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments